Angiopoietin Dysregulation to Predict Adverse Outcomes in Cardiac Surgery: the Prospective
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event
Study Overview
Brief Summary
Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery.
The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •adult patient scheduled for cardiac surgery under cardiopulmonary bypass
Exclusion Criteria
- •patient less than 18 years old,
- •redo surgery,
- •urgent surgery,
- •endocarditis,
- •aortic root repair surgery
- •aortic dissection
- •heart beating surgery,
- •heart transplantation
Outcomes
Primary Outcomes
correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event
Time Frame: 28 days
major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of major cardiovascular event
Time Frame: 28 days
major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death
Secondary Outcomes
- Correlation between abnormal angiopoietin 2 concentration (ng/ml) and number of postoperative pulmonary complications(28 days)
- Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality at 3 months(3 months)
- Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 6 months(6 months)
- Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 3 months(3 months)
- Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality rate at 12 months(12 months)
- Correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and mortality at 6 months(6 months)
- Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of postoperative pulmonary complications(28 days)
- Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality rate at 12 months(12 months)